Analyst Scoreboard: 5 Ratings For Integra Lifesciences
Portfolio Pulse from Benzinga Insights
Analysts have provided diverse opinions on Integra Lifesciences (NASDAQ:IART) with recent ratings ranging from bullish to bearish. Over the past quarter, there have been 3 somewhat bullish and 2 indifferent ratings. The average 12-month price target for IART is $48.6, reflecting a 9.21% increase from the previous target of $44.50. Key analysts from JMP Securities, Truist Securities, and Wells Fargo have adjusted their ratings and price targets, indicating a nuanced view of the company's financial health and market position. Integra Lifesciences, a medical equipment company, faces challenges in revenue growth and debt management but excels in net margin, ROE, and ROA.
February 29, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Integra Lifesciences has received mixed analyst ratings with a new average 12-month price target of $48.6, indicating a positive outlook. Despite facing revenue growth challenges and high debt levels, the company's strong net margin, ROE, and ROA suggest efficient management and financial health.
The mixed analyst ratings with a positive adjustment in the 12-month price target suggest a cautiously optimistic outlook for Integra Lifesciences. The company's financial indicators such as net margin, ROE, and ROA are strong, despite challenges in revenue growth and debt management. This combination of factors leads to a positive short-term impact on the stock, as the market may react favorably to the analyst ratings and the company's underlying financial health.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100